Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
breast cancer
Biotech
Arvinas lays off 33% of staff, axes Pfizer-partnered trials
Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor degrader R&D plan in the wake of mixed data.
Nick Paul Taylor
May 1, 2025 8:50am
Study illustrates pros, cons of AI readings in 3D mammography
Apr 25, 2025 12:00pm
RadNet to absorb mammography AI developer iCad in $103M deal
Apr 16, 2025 2:05pm
Relay starts 3rd layoff wave in one year, shedding 70 staffers
Apr 4, 2025 11:30am
Pfizer, Arvinas' PROTAC posts mixed results in first ph. 3 test
Mar 11, 2025 10:06am
AstraZeneca’s oral SERD hits goal in phase 3 breast cancer trial
Feb 26, 2025 5:40am
